Cited by 4,148Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.

Innate and adaptive immune cells in the tumor microenvironment

Open access

Gajewski, Thomas F, Schreiber, Hans, Fu, Yang-Xin·2013·Nature Immunology

Open this paper in CoChat — free account

Abstract

Most tumor cells express antigens that can mediate recognition by host CD8(+) T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell-inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system-suppressive pathways. The other major phenotype lacks this T cell-inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2703

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Flagged first, then by citations

Show all 149 references

Research works printed but not linked: 1

Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. (in the press).

Sorted by citations

Items 701–800 of 1,004

Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy
Han, S., Huang, K., Gu, Z., & Wu, J. (2019) · Nanoscale · doi:10.1039/c9nr08086d · Cited by 85
Deep learning-based image analysis methods for brightfield-acquired multiplex immunohistochemistry images
Fassler, D., Abousamra, S., Gupta, R., Chen, C., Zhao, M., Paredes, D., Batool, S. A., Knudsen, B. S., Escobar‐Hoyos, L. F., Shroyer, K. R., et al. (2020) · Diagnostic Pathology · doi:10.1186/s13000-020-01003-0 · Cited by 79
Transplant Oncology in Primary and Metastatic Liver Tumors
Sapisochín, G., Hibi, T., Toso, C., Man, K., Berenguer, M., Heimbach, J. K., Greten, T. F., Pugh, T. J., Dawson, L. A., & Mazzaferro, V. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004071 · Cited by 79
Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model
Zhang, H., Xie, W., Zhang, Y., Dong, X., Liu, C., Yi, J., Zhang, S., Wen, C., Zheng, L., & Wang, H. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00389-3 · Cited by 79
Photothermal and Photodynamic Therapy of Tumors with Plasmonic Nanoparticles: Challenges and Prospects
Bucharskaya, A. B., Khlebtsov, N. G., Khlebtsov, B. N., Maslyakova, G. N., Наволокин, Н. А., Genin, V. D., Genina, E. A., & Tuchin, V. V. (2022) · Materials · doi:10.3390/ma15041606 · Cited by 80
Checkpoint Antibodies but not T Cell–Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation
Hettich, M., Lahoti, J., Prasad, S., & Niedermann, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3451 · Cited by 79
Meta‐Analysis for Correlating Structure of Bioactive Peptides in Foods of Animal Origin with Regard to Effect and Stability
Maestri, E., Pavlićević, M., Montorsi, M., & Marmiroli, N. (2018) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12402 · Cited by 80
The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity
Martin, K., Müller, P., Schreiner, J., Prince, S. S., Lardinois, D., Heinzelmann-Schwarz, V. A., Thommen, D. S., & Zippelius, A. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1565-4 · Cited by 78
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Thomsen, M., Kersten, C., Sørbye, H., Skovlund, E., Glimelius, B. L. G., Pfeiffer, P., Johansen, J. S., Kure, E. H., Ikdahl, T., Tveit, K. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12601 · Cited by 80
Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells
Tanne, A., Muniz, L. R., Puzio-Kuter, A., Leonova, K. I., Gudkov, A. V., Ting, D. T., Monasson, R., Cocco, S., Levine, A. J., Bhardwaj, N., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517584112 · Cited by 74
Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner
Ogony, J. W., Choi, H. J., Lui, A. J., Cristofanilli, M., & Lewis-Wambi, J. S. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0683-7 · Cited by 77
Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells
Shime, H., Maruyama, A., Yoshida, S., Takeda, Y., Matsumoto, M., & Seya, T. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373231 · Cited by 77
Biomarkers of response to immune checkpoint blockade in cancer treatment
Fujii, T., Naing, A., Rolfo, C. D., & Hajjar, J. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.010 · Cited by 77
High expression of CD47 in triple negative breast cancer is associated with epithelial‑mesenchymal transition and poor prognosis
Yuan, J., Shi, X., Chen, C., He, H., Liu, L., Wu, J., & Yan, H. (2019) · Oncology Letters · doi:10.3892/ol.2019.10618 · Cited by 77
The Agpat4/LPA axis in colorectal cancer cells regulates antitumor responses via p38/p65 signaling in macrophages
Zhang, D., Shi, R., Xiang, W., Kang, X., Tang, B., Li, C., Gao, L., Zhang, X., Zhang, L., Dai, R., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0117-y · Cited by 81
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 78
Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy
Qu, X., Zhou, D. F., Lu, J., Qin, D., Zhou, J. M., & Liu, H.-J. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.12.010 · Cited by 78
Friend or foe?
Colangelo, T., Polcaro, G., Muccillo, L., D'Agostino, G., Rosato, V., Ziccardi, P., Lupo, A., Mazzoccoli, G., Sabatino, L., & Colantuoni, V. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.11.001 · Cited by 83
Prostate Cancer and Neuroendocrine Differentiation: More Neuronal, Less Endocrine?
Grigore, A. D., Ben‐Jacob, E., & Farach‐Carson, M. C. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00037 · Cited by 78
Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma
Großmann, P., Gutman, D. A., Dunn, W. D., Holder, C. A., & Aerts, H. J. W. L. (2016) · BMC Cancer · doi:10.1186/s12885-016-2659-5 · Cited by 77
Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity
Li, L., Li, Y., Cheng, S., Fan, Z., Shen, Z., Xue, W., Zheng, Y., Li, F., Wang, D., Zhang, K., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1027-x · Cited by 78
Centrosome dysfunction: a link between senescence and tumor immunity
Wu, Q., Li, B., Liu, L., Sun, S., & Sun, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00214-7 · Cited by 78
Construction of a lipid metabolism‐related and immune‐associated prognostic signature for hepatocellular carcinoma
Hu, B., Yang, X., & Sang, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3353 · Cited by 71
SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected and Non‐Injected Lesions
Srinivasan, S., Yee, N. A., Wu, K., Zakharian, M., Mahmoodi, A., Royzen, M., & Oneto, J. M. M. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000243 · Cited by 76
Circadian clock: a regulator of the immunity in cancer
Zhang, Z., Zeng, P., Gao, W., Zhou, Q., Feng, T., & Tian, X. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00721-2 · Cited by 80
Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy
Tang, Q., Yang, S., He, G., Zheng, H., Zhang, S., Liu, J., Wei, S., Fan, Q., Peng, X., Li, X., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215823 · Cited by 77
Hypoxic glioma-derived exosomal miR-25-3p promotes macrophage M2 polarization by activating the PI3K-AKT-mTOR signaling pathway
Xue, Z., Liu, J., Xing, W., Mu, F., Wu, Y., Zhao, J., Liu, X., Wang, D., Wang, J., Li, X., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02888-5 · Cited by 79
HDAC5 controls the functions of Foxp3+ T‐regulatory and CD8+ T cells
Xiao, H., Jiao, J., Wang, L., O’Brien, S., Newick, K., Wang, L. S., Falkensammer, E., Liu, Y., Han, R., Kapoor, V., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29979 · Cited by 76
Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy
Khoury, T., Nagrale, V., Opyrchal, M., Peng, X., Wang, D., & Yao, S. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000466 · Cited by 75
Colorectal cancer prevention: Immune modulation taking the stage
Fletcher, R., Wang, Y., Schoen, R. E., Finn, O. J., Yu, J., & Zhang, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.12.002 · Cited by 82
Emerging approaches to study cell-cell interactions in tumor microenvironment
Nishida‐Aoki, N., & Gujral, T. S. (2019) · Oncotarget · doi:10.18632/oncotarget.26585 · Cited by 76
Quantifying Cancer Epithelial-Mesenchymal Plasticity and its Association with Stemness and Immune Response
Jia, D., Li, X., Bocci, F., Tripathi, S., Deng, Y., Jolly, M. K., Onuchic, J. N., & Levine, H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050725 · Cited by 72
Self-evolved hydrogen peroxide boosts photothermal-promoted tumor-specific nanocatalytic therapy
Gao, S., Lu, X., Zhu, P., Lin, H., Yu, L., Yao, H., Wei, C., Chen, Y., & Shi, J. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00525k · Cited by 75
The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy
Neophytou, C. M., Pierides, C., Christodoulou, M., Costeas, P., Kyriakou, T.-C., & Papageorgis, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00899 · Cited by 75
Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Patients Undergoing Surgery for Oral Cavity Cancer
Tsai, Y., Ko, C.-A., Chen, H., Hsu, C., Lai, C., Lee, Y., Tsai, M., Chang, G., Huang, E. I., & Fang, K. (2022) · Journal of Cancer · doi:10.7150/jca.74930 · Cited by 77
Nanomaterials: small particles show huge possibilities for cancer immunotherapy
Chen, Z., Yue, Z., Yang, K., & Li, S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01692-3 · Cited by 76
Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology
Minici, R., Siciliano, M. A., Ammendola, M., Santoro, R., Barbieri, V., Ranieri, G., & Laganà, D. (2022) · Cancers · doi:10.3390/cancers15010257 · Cited by 80
Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway
Cheng, L., Zhang, P., Liu, Y., Liu, Z., Tang, J., Xu, L., & Liu, J. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122259 · Cited by 79
tRNA-derived small RNAs in human cancers: roles, mechanisms, and clinical application
Zhou, M., He, X., Zhang, J., Mei, C., Zhong, B., & Ou, C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01992-2 · Cited by 79
The importance of the tumor microenvironment in the therapeutic management of cancer
Pottier, C., Wheatherspoon, A., Roncarati, P., Longuespée, R., Herfs, M. F., Duray, A., Delvenne, P., & Quatresooz, P. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1059279 · Cited by 80
Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement
Morgan, M. M., Johnson, B. P., Livingston, M. K., Schuler, L. A., Alarid, E. T., Sung, K. E., & Beebe, D. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.05.007 · Cited by 75
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 76
Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer
Hung, R. J., Ulrich, C. M., Goode, E. L., Brhane, Y., Muir, K. R., Chan, A. T., Marchand, L. L., Schildkraut, J. M., Witte, J. S., Eeles, R. A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv246 · Cited by 77
Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice
da Silva, I. P., & Long, G. V. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000405 · Cited by 75
T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors
Hu, J., Sun, C., Bernatchez, C., Xia, X., Hwu, P., Dotti, G., & Li, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1365 · Cited by 74
LncRNA RP11-361F15.2 promotes osteosarcoma tumorigenesis by inhibiting M2-Like polarization of tumor-associated macrophages of CPEB4
Dong, Y., Liu, K., Fan, L., Liang, W., Xu, T., Jiang, W., Lu, H., Jiang, J., Wang, C. C., Li, G., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.12.041 · Cited by 74
The Scavenger Receptor MARCO Expressed by Tumor-Associated Macrophages Are Highly Associated With Poor Pancreatic Cancer Prognosis
Shi, B., Chu, J., Huang, T., Wang, X., Li, Q., Gao, Q., Xia, Q., & Luo, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.771488 · Cited by 74
Chemokine (C-C Motif) Ligand 5 is Involved in Tumor-Associated Dendritic Cell-Mediated Colon Cancer Progression Through Non-Coding RNA MALAT-1
Kan, J., Wu, D., Yu, F., Wu, C., Ho, Y., Chiu, Y., Jian, S., Hung, J., Wang, J., & Kuo, P. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24918 · Cited by 74
Polarization of Tissue-Resident TFH-Like Cells in Human Hepatoma Bridges Innate Monocyte Inflammation and M2b Macrophage Polarization
Chen, M., Xiao, C., Lao, X., Yuan, W., Liu, R., Zeng, Q., Wang, J., Ouyang, F., Chen, D., Chan, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0329 · Cited by 74
Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Awad, M. M., Jones, R. E., Liu, H., Lizotte, P. H., Ivanova, E. V., Kulkarni, M. M., Herter-Sprie, G. S., Liao, X., Santos, A. A., Bittinger, M. A., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0171 · Cited by 75
One microenvironment does not fit all: heterogeneity beyond cancer cells
Kim, I. S., & Zhang, X. H.-F. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9643-z · Cited by 75
Are BiTEs the “missing link” in cancer therapy?
Suryadevara, C. M., Gedeon, P. C., Sanchez-Perez, L. A., Verla, T. G., Alvarez-Breckenridge, C. A., Choi, B. D., Fecci, P. E., & Sampson, J. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008339 · Cited by 72
Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis
Malinzi, J., Ouifki, R., Eladdadi, A., Torres, D. F. M., & White, K. A. J. (2018) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2018066 · Cited by 73
Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer
Zhou, F., Gao, J., Xu, Z., Li, T., Gao, A., Sun, F. Z., Wang, F., Wang, W., Geng, Y., Zhang, F., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101025 · Cited by 71
Emerging nanomedicines for effective breast cancer immunotherapy
Bahreyni, A., Mohamud, Y., & Luo, H. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00741-z · Cited by 73
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
Budczies, J., Kirchner, M., Kluck, K., Kazdal, D. N., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J. F., Winter, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1860586 · Cited by 74
The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy
Li, Z., Li, Y., Gao, J., Fu, Y., Hua, P., Jing, Y., Cai, M., Wang, H., & Tong, T. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119150 · Cited by 76
Self-citation
A Nanoplatform to Amplify Apoptosis-to-Pyroptosis Immunotherapy via Immunomodulation of Myeloid-Derived Suppressor Cells
Zhou, S., Shang, Q., Ji, J., & Luan, Y. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c16154 · Cited by 74
Untethered Microrobots for Active Drug Delivery: From Rational Design to Clinical Settings
Liu, D., Wang, T., & Lu, Y. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202102253 · Cited by 74
Gallic acid induces T-helper-1-like T reg cells and strengthens immune checkpoint blockade efficacy
Deng, B., Yang, B., Chen, J., Wang, S., Zhang, W., Guo, Y., Han, Y., Li, H., Dang, Y., Yuan, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004037 · Cited by 75
The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment
Lian, J., Liang, Y., Zhang, H., Lan, M., Ye, Z., Lin, B., Qiu, X., & Zeng, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912279 · Cited by 75
Colorectal cancer: Metabolic interactions reshape the tumor microenvironment
Chen, J., Zhu, H., Yin, Y., Jia, S., & Luo, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188797 · Cited by 75
ENPP1 Immunobiology as a Therapeutic Target
de Córdoba, B. R., Martínez‐Monge, R., & Lecanda, F. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1681 · Cited by 79
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation
Luo, F., Li, H., Ma, W., Cao, J., Chen, Q., Lu, F., Qiu, M., Zhou, P., Xia, Z., Zeng, K., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01112-y · Cited by 77
Natural Killer Cells Eradicate Galectin-1–Deficient Glioma in the Absence of Adaptive Immunity
Baker, G. J., Chockley, P. J., Yadav, V. N., Doherty, R. E., Ritt, M., Sivaramakrishnan, S., Castro, M. G., & Lowenstein, P. R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1203 · Cited by 74
Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment
Li, X., Jolly, M. K., George, J. T., Pienta, K. J., & Levine, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00010 · Cited by 73
Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer
Wei, T.-T., Lin, Y., Tang, S.-P., Luo, C.-K., Tsai, C.-C., Shun, C., & Chen, C. (2019) · Oncogene · doi:10.1038/s41388-019-0999-8 · Cited by 73
Actors on the Scene: Immune Cells in the Myeloma Niche
Leone, P., Solimando, A. G., Malerba, E., Fasano, R., Buonavoglia, A., Pappagallo, F., Re, V. D., Argentiero, A., Silvestris, N., Vacca, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.599098 · Cited by 73
Innate immune evasion revealed in a colorectal zebrafish xenograft model
Póvoa, V., de Almeida, C. R., Maia-Gil, M., Sobral, D., Domingues, M., Martínez-López, M. F., Fuzeta, M. D. A., Silva, C., Grosso, A. R., & Fior, R. (2021) · Nature Communications · doi:10.1038/s41467-021-21421-y · Cited by 72
CCRL2 promotes antitumor T-cell immunity via amplifying TLR4-mediated immunostimulatory macrophage activation
Yin, W., Li, Y., Song, Y. Y., Zhang, J., Wu, C., Chen, Y., Miao, Y., Lin, C., Lin, Y., Yan, D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024171118 · Cited by 70
Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges
Nie, Z., Chen, M., Gao, Y., Huang, D., Cao, H., Peng, Y., Guo, N., Wang, F., & Zhang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.879317 · Cited by 83
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 84
Immunotherapy in Gastrointestinal Cancers
Procaccio, L., Schirripa, M., Fassan, M., Vecchione, L., Bergamo, F., Prete, A. A., Intini, R., Manai, C., Dadduzio, V., Boscolo, A., et al. (2017) · BioMed Research International · doi:10.1155/2017/4346576 · Cited by 72
The Multiple Layers of the Tumor Environment
Laplane, L., Duluc, D., Larmonier, N., Pradeu, T., & Bikfalvi, A. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.10.002 · Cited by 74
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Wesolowski, R., Duggan, M. C., Stiff, A., Markowitz, J., Trikha, P., Levine, K. M., Schoenfield, L., Abdel-Rasoul, M., Layman, R., Ramaswamy, B., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2038-3 · Cited by 71
Cancer vaccines using supramolecular hydrogels of NSAID-modified peptides as adjuvants abolish tumorigenesis
Wang, Z., Liang, C., Shi, F., He, T., Gong, C., Wang, L., & Yang, Z. (2017) · Nanoscale · doi:10.1039/c7nr04990k · Cited by 71
Combining immunotherapy and radiotherapy in lung cancer
Bhalla, N., Brooker, R. C., & Brada, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.107 · Cited by 71
Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology
Failmezger, H., Muralidhar, S., Rullan, A., de Andrea, C. E., Sahai, E. A., & Yuan, Y. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2268 · Cited by 76
Electrospun Shape Memory Polymer Micro-/Nanofibers and Tailoring Their Roles for Biomedical Applications
Zare, M., Davoodi, P., & Ramakrishna, S. (2021) · Nanomaterials · doi:10.3390/nano11040933 · Cited by 73
Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer
Qin, A., Coffey, D. G., Warren, E. H., & Ramnath, N. (2016) · Cancer Medicine · doi:10.1002/cam4.819 · Cited by 72
Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy
Liu, M., Zhou, J., Chen, Z., & Cheng, A. S. L. (2016) · The Journal of Pathology · doi:10.1002/path.4832 · Cited by 69
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy
Ghoneim, H. E., Zamora, A. E., Thomas, P. G., & Youngblood, B. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.002 · Cited by 71
T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire
Beausang, J. F., Wheeler, A. J., Chan, N. H., Hanft, V. R., Dirbas, F. M., Jeffrey, S. S., & Quake, S. R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713863114 · Cited by 71
Inflammation-on-a-Chip: Probing the Immune System Ex Vivo
Irimia, D., & Wang, X. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.03.011 · Cited by 74
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival
Brück, O. E., Dufva, O., Hohtari, H. R., Blom, S., Turkki, R., Ilander, M. M., Kovanen, P. E., Pallaud, C., Ramos, P. M., Lähteenmäki, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000792 · Cited by 71
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13081 · Cited by 72
Targeting complement-mediated immunoregulation for cancer immunotherapy
Kolev, M. V., & Markiewski, M. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.003 · Cited by 70
High Dimensional Imaging Mass Cytometry Panel to Visualize the Tumor Immune Microenvironment Contexture
Elaldi, R., Hémon, P., Petti, L., Cosson, E., Desrues, B., Sudaka, A., Poissonnet, G., Obberghen‐Schilling, E. V., Pers, J., Braud, V. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666233 · Cited by 76
Hyalase-Mediated Cascade Degradation of a Matrix Barrier and Immune Cell Penetration by a Photothermal Microneedle for Efficient Anticancer Therapy
He, T., Luo, Y., Zhang, Q., Men, Z., Su, T., Fan, L., Chen, H., & Shen, T. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c06725 · Cited by 70
Relationship between Th17 immune response and cancer
Marques, H. S., de Brito, B. B., da Silva, F. A. F., Santos, M. L. C., de Souza, J. C. B., Correia, T. M. L., Lopes, L. W., Neres, N. S. D. M., Dórea, R. S. D. M., Dantas, A. C. S., et al. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i10.845 · Cited by 76
Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells
Park, S., Kim, M.-J., Park, S.-A., Kim, J.-S., Min, K.-N., Kim, D., Lim, W., Nam, J., & Sheen, Y. Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6063 · Cited by 70
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
Zheng, W., Skowron, K. B., Namm, J. P., Burnette, B., Fernandez, C., Arina, A., Liang, H. L., Spiotto, M. T., Posner, M. C., Fu, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9915 · Cited by 69
Self-citation
Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck
Hanna, G. J., Liu, H., Jones, R. E., Bacay, A. F., Lizotte, P. H., Ivanova, E. V., Bittinger, M. A., Cavanaugh, M. E., Rode, A. J., Schoenfeld, J. D., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.02.005 · Cited by 70
Cellular Plasticity in Breast Cancer Progression and Therapy
Kong, D., Hughes, C. J., & Ford, H. L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00072 · Cited by 73
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines
Viswanath, D. I., Liu, H., Huston, D. P., Chua, C. Y. X., & Grattoni, A. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121297 · Cited by 72
Biomanufacturing of Therapeutic Cells: State of the Art, Current Challenges, and Future Perspectives
Roh, K., Nerem, R. M., & Roy, K. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-033559 · Cited by 67
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages
Jiang, C., Yuan, F., Wang, J., & Wu, L. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.12.002 · Cited by 69
Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach
Mahasa, K. J., Eladdadi, A., de Pillis, L. G., & Ouifki, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184347 · Cited by 69
Immunological landscape of consensus clusters in colorectal cancer
Karpiński, P., Rossowska, J., & Sasiadek, M. M. (2017) · Oncotarget · doi:10.18632/oncotarget.22169 · Cited by 68
Potentiating prostate cancer immunotherapy with oncolytic viruses
Lee, P. C., & Gujar, S. A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.10 · Cited by 70

Authors: Gajewski, T. F., Schreiber, H., & Fu, Y.-X.
Affiliations: University of Chicago (US)
Corresponding author: Gajewski, Thomas F
ORCID: Schreiber, Hans
Fu, Yang-Xin
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-09-18
Volume: 14
Issue: 10
Pages: 1014-1022
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2703
PMC: PMC4118725
OpenAlex: W2042699075
Cited by: 4,148
References: 149
Citations by year: 2026: 187 · 2025: 310 · 2024: 432 · 2023: 486 · 2022: 443 · 2021: 522 · 2020: 372 · 2019: 315 · 2018: 290 · 2017: 290 · 2016: 240 · 2015: 162 · 2014: 82 · 2013: 1
FWCI: 17.11
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA161005, R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: tumor microenvironment, tumor immune evasion, innate immunity, adaptive immunity, CD8+ T cells, immune exclusion, type I interferon signature, chemokine profile, immune checkpoint blockade, cancer immunotherapy
MeSH terms: Animals, Dendritic Cells, Humans, Immunity, Innate, Lymphocyte Activation, Neoplasms, T-Lymphocyte Subsets, Stromal Cells, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Innate and adaptive immune cells in the tumor microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks